RUNX3 regulates hepatocellular carcinoma cell metastasis via targeting miR-186/E-cadherin/EMT pathway

作者：Yuli Gou, Fangbing Zhai, Liang Zhang, Lan Cui · 发表于：Oncotarget · 年份：2017 · DOI：10.18632/oncotarget.18424 · 被引用次数：31 · 研究领域：Cancer-related molecular mechanisms research、MicroRNA in disease regulation、Circular RNAs in diseases

// Yuli Gou 1, * , Fangbing Zhai 2, * , Liang Zhang 3 and Lan Cui 4 1 Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian 116027, Liaoning, China 2 Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian 116027, Liaoning, China 3 Department of Interventional Therapy, The Second Affiliated Hospital of Dalian Medical University, Dalian 116027, Liaoning, China 4 Department of Ophthalmology, The Second Affiliated Hospital of Dalian Medical University, Dalian 116027, Liaoning, China * These authors have contributed equally to this work as the co-first authors Correspondence to: Liang Zhang, email: zhangliangdlmu@163.com Lan Cui, email: cuilandlmu@163.com Keywords: RUNX3, miR-186, E-cadherin, HCC Received: May 04, 2017      Accepted: May 23, 2017      Published: June 09, 2017 ABSTRACT Runt-related transcription factor 3 (RUNX3) has been reported as a tumor suppressor in some kinds of cancers. In the present study, hepatocellular carcinoma (HCC) microarray analysis showed that RUNX3 expression was significantly lower in HCC tissues compared with that in adjacent non-tumor tissues, and was negatively associated with metastasis and TNM stage. RUNX3 was an independently prognostic factor for 5-year overall and disease-free patient survival. Mechanically, RUNX3 repressed metastasis and invasion of HCC, and increased E-cadherin expression. RUNX3 also...